Galaxy Balance

Cory Smith
  • 0,0 (0)
  • Scienze biologiche

Galaxy Balance explores the frontier where biology, technology and consciousness meet. Each episode brings together pioneers shaping our collective future, from genome engineers and AI builders to longevity researchers, space explorers, and mindfulness practitioners. Hosted by Cory Smith, the conversations dive deep into how these seemingly distant fields form an interconnected ecosystem, one that balance innovation with introspection, science with spirit, and ambition with awareness. At its core, Galaxy Balance is about integration; the idea that our greatest leaps forward happen when disciplines collide. The same algorithms that decode galaxies can help us understand genomes; the same principles that govern consciousness can illuminate AI. Through long-form, unscripted dialogue, the show invites listeners to zoom out from the silos of specialization and see the larger pattern: a living system of intelligence evolving across scales – molecular, planetary, and cosmic.

  1. 7 set

    Humanity May Become the Little Green Men

    If the universe contains billions of potentially habitable worlds, where is everybody? Dr. Terry Adair, author of Where Are the Little Green Men? The Adair Hypothesis, joins Galaxy Balance to examine the Fermi paradox through the lens of energy. His hypothesis proposes that an advanced technological civilization requires access to an abundant, dense, storable, transportable, and scalable energy supply. The conversation traces Earth’s energetic evolution from hydrothermal chemistry and photosynthesis to fire, fossil fuels, nuclear fission, and fusion. Terry explains how photosynthesis enabled complex life while also creating the ancient reserves of coal, oil, and natural gas that eventually powered industrial civilization. He argues that this unlikely sequence may represent a series of filters preventing intelligent life elsewhere from producing detectable technology or reaching other stars. We also explore the Drake equation, abiogenesis, the evolution of complex life, the technological limitations of ocean worlds, the challenges surrounding red dwarf stars, and the laws of thermodynamics that constrain every possible civilization. Terry outlines how fusion energy could eventually enable plasma drives, antimatter production, and spacecraft capable of reaching a meaningful fraction of the speed of light. The episode closes with an optimistic vision of humanity’s long-term future. If we continue expanding our scientific knowledge and energy capabilities, humans may eventually become the interstellar visitors that other civilizations look toward the sky hoping to find. 00:00 - Why the Fermi paradox belongs at the center of this conversation 03:37 - How Adair’s background led him to an energy-based hypothesis 04:20 - What the Fermi paradox actually means 08:14 - Drake equation, exoplanets, and the Great Filter 10:23 - Why the Drake equation is a framework, not an exact answer 11:47 - Why abiogenesis and intelligence are not the same question 13:29 - Earth’s evolutionary milestones from microbes to technology 15:10 - Why photosynthesis is the breaking point in life’s history 18:28 - The difference between abundant energy and usable energy 21:49 - Endosymbiosis, mitochondria, and the energy jump in complex life 23:51 - Why CO2 is the raw material behind plant structure 26:19 - How biomass became coal, oil, and natural gas 29:25 - Where uranium and thorium come from 31:46 - Why nuclear fusion is central to future civilization 33:34 - Entropy, disorder, and why perpetual motion fails 38:03 - The limits of fossil fuels and the case for nuclear fission 40:02 - Weapons, waste, and why small modular reactors matter 43:20 - The Adair Hypothesis, defined 44:14 - Fire as humanity’s first technology 47:27 - The photosynthetic trap and why fossil fuels changed civilization 49:58 - How much energy humanity has burned in 200 years 51:21 - Could an aquatic species build technology without fire? 52:32 - From Democritus to quarks: what matter really is 56:22 - Why energy access on Earth is still an equity issue 58:51 - Antimatter, plasma drives, and propulsion limits 62:47 - Why fusion-powered travel is a 300 to 400 year project 64:21 - Humans as the future “little green men” 65:21 - Why Star Wars is Adair’s favorite science fiction reference

  2. 24 ago

    Can We Make a Drug for One Person?

    What if we could design a medicine for a single person? Casey McPherson was a musician and songwriter when his daughter Rose was diagnosed with an ultra-rare neurogenetic disease. There was no approved treatment and no clear path forward. Rather than accepting that answer, Casey began learning genetics, building a network of scientists, and ultimately creating the infrastructure needed to develop a treatment for his daughter. Today, Casey is the CEO and co-founder of Alpha Rose Therapeutics, where his team is working to make individualized genetic medicine scalable. Their approach combines antisense oligonucleotides, patient-derived stem cells, AI-guided therapeutic design, automation, and a new economic model for diseases that traditional drug development often leaves behind. We discuss how Alpha Rose reduced a therapeutic amenability analysis that once took months to just minutes using AI, why Casey believes drug development should eventually be approved as a repeatable process rather than one drug at a time, and how point-of-care synthesis could allow personalized genetic medicines to be produced rapidly for individual patients. We also explore autonomous laboratories, AI scientists, patient-derived iPSCs and brain organoids, the economics of rare disease, genetic enhancement, and a future of medicine that looks increasingly like the sick bay of Star Trek: understand the unique biology of the patient, design the intervention, synthesize it, and treat them. Casey's story raises a much bigger question. Are rare diseases really rare, or are they the first glimpse of a future where every disease becomes individualized?   00:00 - Casey McPherson’s path from musician to biotech founder 01:38 - Childhood curiosity: music, programming, electronics, and biology 04:16 - Rose’s diagnosis and the end of the traditional care pathway 07:46 - Learning the problem was bigger than one child 09:59 - Why a foundation and ecosystem had to come first 11:27 - Why Rare Labs was built as a modality agnostic discovery lab 12:24 - Why antisense oligonucleotides made sense for Rose 13:22 - Designing and filtering thousands of ASO candidates 15:13 - Building patient-specific iPSCs and brain organoids 17:25 - Why animal models are mainly a safety tool 20:06 - Why Alpha Rose became a public benefit corporation 23:22 - Regulatory strategy and the path toward a small patient trial 27:35 - How Casey learned drug development by doing 30:30 - The AI amenability study workflow for new patients 33:24 - Turning a rough AI prototype into a validated internal tool 35:34 - Using the tool on every new drug and patient case 36:31 - Why speed matters when families are waiting on treatment 37:54 - Rare disease as a business model problem, not just a science problem 43:02 - The next decade of individualized medicine 44:27 - Process approval and point-of-care drug synthesis 46:34 - Beyond rare disease: enhancement and broader applications 48:24 - Why children’s health is so underfunded 51:20 - Why precision medicines can lower development risk 53:33 - Robotics and the fully automated lab of the future 55:46 - Renee, conversational AI, and the scientist-as-assistant future 56:54 - Science fiction influence and the Star Trek medicine model 59:50 - Advice for families and scientists facing genetic disease 1:02:21 - Closing thoughts on individualized disease

  3. 10 ago

    Clarice Aiello: The Hidden Quantum Physics of Biology

    Could life be using quantum physics to sense the world, regulate cellular processes, and respond to magnetic fields? Clarice Aiello is a quantum engineer, Chair of the Board and Chief Scientific Officer at the Quantum Biology Institute, and the founder of the former Quantum Biology Tech Lab at UCLA. Her research explores whether living systems harness quantum phenomena once considered too fragile to survive within warm, noisy cells. In this episode of Galaxy Balance, Clarice explains quantum tunneling, superposition, entanglement, and decoherence through the lens of biology. We discuss how electrons inside proteins may function as nature-made quantum sensors, how weak magnetic fields can influence cellular behavior, and whether engineered magnetic fields could eventually support wound healing, regeneration, and other forms of electromagnetic medicine. Clarice also describes the evidence that birds may use quantum sensing to navigate, why nature could teach us to build better quantum technologies, and how altered magnetic environments may affect organisms traveling to the Moon or Mars. We explore the scientific standards needed to move quantum biology into the mainstream, the limits of current evidence, and the possibility of creating a Star Trek-style tricorder that interacts with biology through precisely designed magnetic fields. The conversation closes with quantum literacy, science fiction, interdisciplinary research, and Clarice’s advice for the next generation of scientists entering one of biology’s strangest emerging frontiers. 0:00 Clarice Aiello’s background and why quantum biology matters 7:12 The long-term vision for magnetic-field-based therapeutics 10:30 Why the field still lacks depth, breadth, and standards 15:30 What quantum physics is, in plain language 19:01 Superposition explained with dimmer-switch logic 26:19 Why decoherence limits quantum effects in warm, wet cells 29:27 What counts as evidence for quantum biology today 32:24 Skepticism about entanglement, microtubules, and consciousness claims 34:37 The double-slit experiment and why observation is often misunderstood 37:11 Mars, the Moon, and why magnetic fields may matter for colonization 41:37 How weak magnetic fields may work at the protein level 44:36 Spin-dependent chemical reactions and biological branching 53:14 Why Clarice thinks nature is effectively a quantum engineer 58:13 Science fiction, Recursion, and what it gets right and wrong about observation 59:05 Why quantum literacy should be part of basic education

  4. 27 lug

    Li Li: Rewiring Skin Aging With AI and mRNA

    00:00 - Introduction to Lily and GLife’s vision for data-driven dermatology 01:20 - Lily’s scientific background 02:43 - Breakthroughs from single-cell atlases 03:50 - The motivation behind founding GLife 04:50 - The importance of treating skin as a foundational organ 05:48 - Discovery of key molecular drivers of aging 06:22 - Challenges of fundraising 07:45 - The novel approach to rejuvenating hair loss through targeted messenger RNA treatments 08:53 - How treatments will be delivered via microneedles and micro patches 09:32 - The potential to alter hair color and explore cosmetic applications 10:06 - Balancing platform discovery engines with the development of first-in-class therapeutics 10:43 - The comprehensiveness of the skin atlas and addressing genetic diversity 11:39 - Technical challenges of capturing skin’s cellular heterogeneity and stem cell populations 12:50 - The importance of isoforms and deep sequencing in understanding gene functions 13:16 - Short-lived messenger RNA as a safe, reversible treatment modality 14:55 - Safety considerations and toxicity management 16:01 - Biodistribution studies and local micro-needle delivery safety 17:00 - Next steps towards clinical trials and regenerative therapies for hair loss 18:08 - The role of big data and omics in understanding skin disorders and aging 19:04 - The significance of isoforms in skin biology and gene function 20:13 - Endogenous vs. modified messenger design for safety and efficacy 21:32 - Potential for multi-gene delivery to enhance hair regrowth and color restoration 22:22 - Conception of patches that work with existing hair without shaving 23:38 - Targeting broad hair loss types and the concept of root causes 24:47 - Modeling hair loss with animal models and regulatory considerations 25:48 - Regulatory perspectives on non-animal models and validation strategies 26:34 - The interplay between genetic and environmental causes of skin aging 27:54 - The biological hub role of specific transcription factors in stress and aging 29:10 - The future of skin biomarkers for diagnosis and personalized health monitoring 30:18 - Leveraging AI’s data integration and precision medicine in dermatology 32:32 - The impact of protein isoforms and post-translational modifications in skin treatment 34:47 - Interest in peptides, small molecules, and biohacking trends for skin health 36:03 - Collaboration between wet labs, computational teams, and clinical partners 36:36 - The significance of internal naming conventions in research and development 37:28 - The high-throughput screening process for key transcription factors 38:13 - Strategies for overexpressing target genes in therapeutic design 39:00 - AI’s role in accelerating discovery and development pipelines in biotech 40:39 - Addressing data quality, heterogeneity, and integration challenges in big datasets 44:12 - Envisioning personalized skincare driven by genomics and AI 44:56 - The inspiring concept that ancient technologies now seem like magic 45:24 - Challenges in bringing novel dermatological treatments through trials and regulation 47:42 - The evolving role of AI in drug quality control and documentation 48:11 - Unique advantages of Lily’s targeted mRNA approach over other modalities 49:22 - Using skin as a model system for broader human biology insights 50:28 - Perspectives on epigenetic reprogramming and cellular re-differentiation 51:22 - Fundraising experiences and strategic positioning for biotech development 52:21 - The influence of science fiction, especially “Three Body Problem” and “Interstellar,” on Lily’s vision 54:24 - Advice to young scientists: read widely, think deeply, and dream big

  5. 13 lug

    Aditya Kunjapur: Bringing New Chemistry to Life

    What does it take to bring new chemistry to life? In this episode of Galaxy Balance, Cory Smith speaks with Aditya Kunjapur, Associate Professor of Chemical and Biomolecular Engineering at the University of Delaware, about genetic code expansion, non-standard amino acids, engineered microbes, and the future of synthetic biology. Aditya’s lab explores how biology can be programmed to biosynthesize chemical groups that are rare or absent in nature, install those new building blocks into proteins, and make microbial survival depend on synthetic chemistry. The conversation moves from his early path through energy and chemical engineering, to his time in George Church’s lab, to the founding of Nitro Biosciences and the use of expanded genetic codes for next generation vaccine platforms. They discuss how non-standard amino acids can act as chemical flags for the immune system, how live microbes could produce antigens inside the body, and why genetic code expansion may open new approaches to vaccines, biocontainment, agriculture, environmental engineering, and planetary protection. The episode also explores synthetic auxotrophy, engineered microbial dependence, plant controlled microbial survival, plastic degradation, agricultural probiotics, bioenergy, AI tools for non-standard amino acids, and the science fiction lessons behind containment, from Jurassic Park to modern AI. This is a conversation about rewriting the language of life, not only to understand biology, but to give it new chemistry, new safeguards, and new possibilities. Timestamps: 00:00 - Engineering microbes for space: Bacillus subtilis and biological containment 02:28 - Aditya’s pathway into synthetic biology and innovative chemistry 05:46 - Transitioning from industry internships to academia and entrepreneurship 10:16 - Founding Nitro Biosciences: balancing entrepreneurship with academic research 16:31 - Genetic code expansion and its potential to elicit immune responses 22:41 - The scarcity and potential of non-standard amino acids in life 27:26 - Detecting extraterrestrial life and the shared building blocks of biology 36:49 - Synthetic oxytrophy and microbial biocontainment strategies 44:01 - Reducing herbicide reliance with engineered microbes in agriculture 52:53 - Computational tools and AI for non-standard amino acid research 54:53 - Bioenergy and sustainability: bio-catalysis innovations 59:08 - How science fiction influences bioengineering and AI safety considerations

  6. 29 giu

    Erik Aznauryan: Writing Genes at Scale

    Erik Aznauryan, CEO and co-founder of HarborSite, joins Galaxy Balance to explore the next frontier of genome engineering: moving beyond small edits and toward precise, large-scale DNA insertion. Erik traces his path from Armenia and medical school to Europe, the Church Lab, and eventually founding HarborSite with a mission to make gene insertion safer, more durable, and more programmable. The conversation dives into recombinases, safe harbor sites, payload size limits, delivery vehicles, in vivo validation, AI-driven protein engineering, and the therapeutic promise of inserting full genes or even entire genetic programs into the genome. Cory and Erik also discuss rare disease, cell therapy, skin and liver targeting, regulatory bottlenecks, animal models, funding shifts in biotech, and the long-term possibility of human enhancement in an age of AI. At the edge of science fiction and translational medicine, this episode asks what becomes possible when genome engineering evolves from editing biology to writing biology at scale 00:00 — The North Star for genome engineering 00:36 — Introduction to Erik and HarborSite 01:39 — Erik’s path into science 02:36 — Early fascination with cloning and genome engineering 03:21 — Cory’s own early inspiration 04:03 — Why genome engineering matters 05:24 — Ethical questions around germline engineering 06:37 — Why early-stage intervention matters 07:51 — Technical progress and disease-specific editing 09:25 — Why HarborSite was founded 10:50 — Recombinases as the core technology 12:15 — Engineering recombinases for new DNA targets 13:12 — Novel genomic safe harbors 14:18 — How safe harbors are selected and validated 15:36 — How much target specificity can be changed? 16:36 — Why lifelong expression matters 17:29 — Testing durability in culture and in vivo 18:26 — The appeal of the albumin locus 19:15 — Endogenous production of biologics 20:59 — Startup challenges and fundraising 22:28 — Why LabCentral is valuable 23:07 — AI BioHub and large proprietary datasets 24:08 — AI’s role in model development 25:11 — Practical uses of AI in biotech startups 26:51 — How the team handles data analysis 27:56 — What the therapeutic product looks like 28:52 — First target tissues: liver and T cells 30:27 — Testing off-target integration 31:27 — Balancing specificity and efficiency 32:24 — Lessons from CAR-T and random integration 33:40 — Why recombinase systems may be safer 34:39 — Payload size and delivery constraints 35:35 — Delivery strategies under consideration 38:09 — Simpler donor DNA formats 39:38 — Platform company and therapeutic company 40:59 — The key milestone: in vivo validation 41:48 — HarborSite’s pre-seed raise 43:05 — How VC expectations have shifted 44:26 — Choosing the right in vivo model 46:22 — The continued importance of mouse studies 48:23 — Global regulatory differences 50:10 — Science funding in the U.S. 52:40 — Synthetic biology in space 54:34 — Enhancement and self-directed health 57:40 — Science fiction and inspiration 59:34 — Advice for young scientists 60:31 — Closing remarks

  7. 15 giu

    Intertwined Biosciences: Engineering Evolution for Human Health

    Max Rye and Evan Appleton of Intertwined Bio join Galaxy Balance to explore one of the boldest ideas in modern biology: borrowing nature’s most extreme traits and translating them into human health. From horses that resist liver cirrhosis to naked mole rats, bowhead whales, radiation resistant organisms, hibernating animals, and the future of humans in space, this conversation asks what becomes possible when evolution itself becomes a design library. Max and Evan explain how Intertwined Bio is using synthetic biology, gene editing, AI, virtual macrophages, and agentic systems to identify traits from extraordinary animals and test whether those adaptations can be engineered into human cells. We discuss liver fibrosis, DNA damage repair, innate immune engineering, longevity, space radiation, de extinction, Colossal Biosciences, the future of virtual cells, and the ethical line between therapy and enhancement. This is a conversation about turning science fiction into biology. 00:00 - Introduction to Intertwined Bio and their innovative approach 01:01 - The origins and motivations of Max and Evan in biotech 04:56 - Scientific foundation: Borrowing traits from long-lived and resilient animals 07:16 - Why now? Recent technological advances enabling these innovations 10:46 - Role of AI in understanding complex biological systems and virtual cell modeling 14:17 - Delivery strategies for genetic modifications in humans 18:19 - Regulatory pathways and ethical boundaries in gene editing 22:25 - The potential of junk DNA variants and regulatory engineering 27:09 - The potential impact on sports animals and broader applications 31:12 - Industry landscape, collaboration, and competition 33:21 - Building a startup: team dynamics, trust, and early steps 35:58 - Insights on other biotech ventures like AstroMech and their directions 38:39 - Space applications: radiation resistance, hibernation, and life support systems 43:01 - Prioritizing targets using AI and high-throughput screening 48:31 - Broader prospects: aging, longevity, and the OZEMPIC effect 52:44 - Focus on innate immune system engineering and virtual cell development 57:15 - Strategies for macrophage gene editing and cell type targeting 1:01:36 - Bottlenecks in lab throughput and cell growth limitations 1:04:30 - The influence of science fiction on biotech innovation and ethical outlooks 1:06:14 - Closing thoughts: science fiction as inspiration and the rapid transition of ideas into reality

  8. 1 giu

    Charles Fracchia: Securing the Bioeconomy

    In this episode of Galaxy Balance, I sit down with Charles Fracchia to explore the emerging infrastructure layer of synthetic biology. We discuss the future of secure and scalable bioengineering, the role of community laboratories in accelerating innovation, and how biology is evolving into a programmable technology platform. Charles shares the story behind BioBright, the creation of Bio-ISAC, and the broader challenge of building resilient systems for a world where genetic engineering becomes increasingly accessible. The conversation moves from cyberbiosecurity and open science to AI-driven biological design, scientific culture, and the growing overlap between software engineering and biotechnology. We also explore the long-term future of human enhancement, decentralized science, and how science fiction continues to shape the ambitions of the next generation of builders working at the frontier of biology. Timestamps: 00:00 - Overcoming cynicism in AI's role in biosecurity 00:40 - Introduction to Charles Fracchia and his pioneering work 02:07 - Charles's background and journey into biotech innovation 04:01 - Balancing classical education with trial-by-fire experience 06:26 - AI as a search tool versus experimental center in biology 08:28 - Developing AI systems for biological experiment automation 11:35 - The founding and evolution of Black Mesa and its mission 14:26 - The importance of digital batch records and AI-assisted QA QC 16:06 - AI's role in drug development, safety, and traceability 18:44 - Ensuring trust and integrity in AI models for biotech applications 22:51 - Addressing data poisoning and ensuring model robustness 24:45 - Strategies for verifying biological data integrity through cryptography and blockchain 33:55 - Future threats like AI-driven bio weapons and safeguarding strategies 42:48 - The importance of operational innovation in accelerating bioeconomy growth 58:25 - Influence of science fiction on biosecurity and innovation 60:11 - Advice for emerging scientists in a rapidly changing landscape 1:02:53 - Closing remarks and future outlook from Charles Fracchia

Elenco completo (27)

Descrizione

Galaxy Balance explores the frontier where biology, technology and consciousness meet. Each episode brings together pioneers shaping our collective future, from genome engineers and AI builders to longevity researchers, space explorers, and mindfulness practitioners. Hosted by Cory Smith, the conversations dive deep into how these seemingly distant fields form an interconnected ecosystem, one that balance innovation with introspection, science with spirit, and ambition with awareness. At its core, Galaxy Balance is about integration; the idea that our greatest leaps forward happen when disciplines collide. The same algorithms that decode galaxies can help us understand genomes; the same principles that govern consciousness can illuminate AI. Through long-form, unscripted dialogue, the show invites listeners to zoom out from the silos of specialization and see the larger pattern: a living system of intelligence evolving across scales – molecular, planetary, and cosmic.

Informazioni

  • Creatore
    Cory Smith
  • Anni di attività
    2025 - 2026
  • Puntate
    27
  • Classificazione
    Contenuti espliciti
  • Copyright
    © 2025 Cory Smith
  • Sito web del podcast
    Galaxy Balance
  • Fornitore